world
2 known investors
GentiBio develops engineered T-regulatory cells (Tregs) as allogeneic therapeutics for autoimmune and inflammatory diseases. The company employs immune-evasive engineering to enable off-the-shelf treatments with scalable manufacturing capabilities.